ArticleBMC public health2025
Associations between internal exposure to acrylamide and sleep health: evidence from NHANES 2013-2016.
Article in BMC public health, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
Acrylamide (AA) is a ubiquitous neurotoxic contaminant. Our objectives were to evaluate associations of internal AA exposure with sleep health outcomes. Data from 2753 adults aged 20-79 years in the National Health and Nutrition Examination Survey (NHANES) was utilized. Internal AA exposure was assessed using hemoglobin adducts and urinary biomarkers. Short sleep duration (SSD) and self-reported trouble sleeping were employed as indicators of sleep health. Markers of systemic inflammation were calculated. Each one-unit increase in ln-transformed hemoglobin adducts of acrylamide (HbAA), hemoglobin adducts of glycidamide (HbGA) and HbAA + HbGA and creatinine-adjusted urinary N-Acetyl-S-(2-carbamoylethyl)-L-cysteine concentration was statistically significantly associated with 1.37-fold (95% confidence interval [CI]: 1.16, 1.62; p = 0.002), 1.41-fold (95%CI: 1.19, 1.68; p = 0.002), 1.43-fold (95%CI: 1.19, 1.70; p = 0.001), and 1.24-fold (95%CI: 1.08, 1.42; p = 0.007) risk in SSD, respectively. The significant associations were strengthened in smokers after stratification by smoking status. Higher AA hemoglobin biomarkers predicted increases in markers of systemic inflammation. In conclusion, internal AA exposure was associated with an increased risk of SSD and elevated systemic inflammation among United States adults. The findings shed light on the potential effects of AA's health threat and future research is warranted to develop intervention strategies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.